Business Wire

Duco Launches Next-Gen AI Automation at SIBOS

29.9.2025 12:28:00 CEST | Business Wire | Press Release

Share

As regulatory deadlines accelerate and data volumes explode, Duco is arming financial institutions with smarter, faster and easier ways to automate. Today Duco introduces AI-powered rules that anyone can build, automated ingestion for any file format, and real time assurance for T+1 settlement readiness in the UK/EU.

Agentic Rule Builder

Duco’s new Agentic Rule Builder is the next step in no-code automation. The company’s Natural Rule Language (NRL) already allowed non-coders to create rules in plain English (‘if X is true then set Y’). But as data and processes grow more complex, even no-code systems require training and become harder to manage.

The Agentic Rule Builder addresses this by letting users describe actions and outcomes the way they would to a colleague. Using a plain English prompt, they can generate and refine NRL rules, edit specific sections, and apply consistent changes across multiple rules.

The tool’s agents map a plan for the rule, build and validate it, and render it in the interface for human validation and full transparency. Early client testing suggests it can cut rule-creation time by half and speed up automation by 60-75%, speeding time to market.

Enhanced AI-Native Data Prep

Building on AIDP – Adaptive Intelligent Document Processing (which intelligently extracts information from PDFs, images, Word files and emails) – this new form of processing learns from content and context, increasing resiliency. Traditional parsing doesn’t take context into account.

Duco has enhanced AI-Native data prep by extending flexible ingestion, enabling low training extraction for faster set up and incorporating Agentic rule builder into the solution. This enables clients to automate more, increase straight through processing, and achieve greater accuracy than with traditional OCR/IDP tools or LLMs alone. All integrated in the Duco platform, eliminating the need for multiple tools in clients' tech stacks.

“AI-powered automation is moving beyond task support to shape how businesses operate,” said Justin Hingorani, Managing Director, AI and Data Prep. “This evolution is not just about speed or efficiency. It is about empowering organisations to respond to client needs and market challenges with agility and confidence. Intelligent automation and industry know-how turn complex post-trade processes into simple, transparent workflows. OCR and IDP were built for static formats. They break the moment data shifts. Our AI-native approach adapts in real time, making it the only sustainable path forward.”

T+0 Assurance Controls for Settlement Evolution

To meet the challenges of T+1 settlement, Duco is launching the only truly cloud-native, AI-native, no code T+0 assurance controls for clients in the UK and Europe. These controls, developed for the North America move to T+1 settlement in 2024, enable clients to move to intra-day, T+0 reconciliations and exception management.

Evidence from last year’s transition shows increasing headcount – in some cases by as much as 18% – doesn’t have a significant impact on fail rates. And with a more than 80% reduction in operational post-trade processing times, manual work – even as the exception – will be untenable. Intra-day reconciliation and exception management will have to become the norm. T+1 requires firms to improve automation capabilities that will support a T+0 operating model.

“The move to T+1 settlement is one of the most significant operational shifts our industry has faced in decades,” said Steve Walsh, Managing Director, Reconciliation. “We’re using critical lessons from North America to ensure the transition in Europe does not require additional headcount. Instead by cutting reconciliation time, firms also create a scalable, future-proof operating model for post-trade processing.”

James Maxfield, Chief Product Officer at Duco, said: “We are moving into an era where automation is not just faster or easier, but smarter and adaptive. Today, our AI agents support rule creation and reconciliation. Soon, they’ll help with anomaly detection, exception management and orchestration of entire processes – always with human oversight where clients need it. This is how firms can build resilience, cut complexity and stay ahead of compressed regulatory deadlines.”

About Duco

Duco is empowering financial services firms to break the bad data cycle that has held the industry back for decades.

We do this with a combination of proprietary technique, innovative cloud computing, no-code and artificial intelligence technology, and deep subject matter expertise.

Our AI-powered operational data automation platform gives firms the ability to unlock full end-to-end reconciliation and automation of their data, regardless of source, format or structure.

By partnering with the industry’s leading firms, we are helping to rethink operating models, increase efficiency, strengthen governance and regulatory compliance, reduce risk, streamline processes and build the workforce of the future.

Over 10,000 users across 30+ countries process billions of data records every week using the platform.

Duco is headquartered in London, with offices in New York, Wroclaw, Antwerp and Singapore. Customers include global banks, investment managers, exchanges and insurance firms, such as CIBC, ING and Man Group. For more information go to www.du.co.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250929875030/en/

Contacts

Greg Noble
greg.noble@cognitomedia.com
Senior Account Executive, Cognito Media
+447983268447

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye